Ignite Creation Date:
2024-05-06 @ 7:53 PM
Last Modification Date:
2024-10-26 @ 3:16 PM
Study NCT ID:
NCT06171360
Status:
RECRUITING
Last Update Posted:
2023-12-14
First Post:
2023-03-13
Brief Title:
A Study of the Gut Microbiome in Hormone Receptor-positive HER2-negative Breast Cancer Treated With CDK46 Inhibitors
Sponsor:
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Organization:
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Study Overview
Official Title:
A Study of the Association of the Gut and Tumor Microbiome With Disease and Treatment Outcome of CDK46 Inhibitors in Hormone Receptor-positive HER2-negative Breast Cancer
Status:
RECRUITING
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CICLIBIOME
Brief Summary:
Ciclibiome is a prospective study including BC patients starting treatment with a CDK46 inhibitor in the metastatic and in the adjuvant setting
This study will focus on the interplay between the gut microbiome its composition and evolution during treatment circulating immune metabolic and cytokine biomarkers before and during treatment and response outcomes to the CDK46 inhibitor
The main aim of the study is to highlight the existence of a microbial immune andor metabolic biomarker of response to CDK46 inhibition in BC assessable by a stool or blood sample examination
Ultimately this will allow to study new potential combination partners for CDK46 inhibitors in escalation trials for poor prognosis patients
This study will focus on the interplay between the gut microbiome its composition and evolution during treatment circulating immune metabolic and cytokine biomarkers before and during treatment and response outcomes to the CDK46 inhibitor
The main aim of the study is to highlight the existence of a microbial immune andor metabolic biomarker of response to CDK46 inhibition in BC assessable by a stool or blood sample examination
Ultimately this will allow to study new potential combination partners for CDK46 inhibitors in escalation trials for poor prognosis patients
Detailed Description:
The combination of endocrine therapy and a CDK46 inhibitor is the preferred treatment option in advanced hormone-receptor positive HR and HER2-negative HER2- breast cancer BC This combination with abemaciclib or ribociclib is now also considered standard of care for early HR HER2- BC deemed at high risk of relapse
Biomarkers predicting response to CDK46 inhibition remain largely unknown Of note research primarily focused on acquired genomic and transcriptomic tumor cell alterations requiring invasive biopsies of tumor content Thus enlarging the scope of biomarkers of response to CDK46 inhibition to more easily accessible biological samples and to areas other than tumoral gene pathway alterations is urgently required
CDK46 inhibitors have been demonstrated to enhance the activity of cytotoxic T cells in BC but without deep knowledge of mechanisms and implications Studies of multiple cancer types have demonstrated the impact of the gut microbiome on the adaptive anti-cancer immunity
Ciclibiome is a prospective study of BC patients starting treatment with a CDK46 inhibitor both in the advanced and adjuvant setting aiming to study the interplay between the gut microbiome its composition and evolution during treatment circulating immune metabolic and cytokine biomarkers before and during treatment and response outcomes to the CDK46 inhibitor
This study will explore the existence of microbial immune and metabolic biomarkers correlated with the clinical outcomes to CDK46 inhibition in BC The aim is to find an easily available biomarker assessable by a stool or blood sample examination
This study will generate new hypotheses that ultimately could give rise to potential combination strategies to test in a population considered of poor prognosis
Biomarkers predicting response to CDK46 inhibition remain largely unknown Of note research primarily focused on acquired genomic and transcriptomic tumor cell alterations requiring invasive biopsies of tumor content Thus enlarging the scope of biomarkers of response to CDK46 inhibition to more easily accessible biological samples and to areas other than tumoral gene pathway alterations is urgently required
CDK46 inhibitors have been demonstrated to enhance the activity of cytotoxic T cells in BC but without deep knowledge of mechanisms and implications Studies of multiple cancer types have demonstrated the impact of the gut microbiome on the adaptive anti-cancer immunity
Ciclibiome is a prospective study of BC patients starting treatment with a CDK46 inhibitor both in the advanced and adjuvant setting aiming to study the interplay between the gut microbiome its composition and evolution during treatment circulating immune metabolic and cytokine biomarkers before and during treatment and response outcomes to the CDK46 inhibitor
This study will explore the existence of microbial immune and metabolic biomarkers correlated with the clinical outcomes to CDK46 inhibition in BC The aim is to find an easily available biomarker assessable by a stool or blood sample examination
This study will generate new hypotheses that ultimately could give rise to potential combination strategies to test in a population considered of poor prognosis
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None